Drug Profile
Diclofenac sodium transdermal - NAL Pharma
Alternative Names: NAL 1219Latest Information Update: 26 May 2022
Price :
$50
*
At a glance
- Originator NAL Pharma
- Class Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown Pain
Most Recent Events
- 26 May 2022 Diclofenac sodium transdermal is still in clinical trials for pain (NAL Pharma pipeline, May 2022)
- 28 Oct 2019 No recent reports of development identified for clinical-Phase-Unknown development in Pain in Unknown (Transdermal, Patch)
- 30 Aug 2016 Chemical structure information added